Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by platelet, leukocyte, and endothelial cell-activating antibodies that recognize ultralarge complexes of platelet factor 4 (PF4) and heparin.\(^1\)\(^-\)\(^4\) Management entails cessation of heparin and initiation of a nonheparin parenteral anticoagulant.\(^5\)\(^-\)\(^7\)

Whether to discontinue heparin and begin a nonheparin anticoagulant in a patient with suspected HIT is a high stakes decision. Delays in implementing therapy in patients with serologically confirmed HIT are associated with an initial 6.1% daily risk of thromboembolism, amputation, and death\(^8\) and a cumulative thrombotic risk of 38 to 53% at 30 days.\(^9\)\(^,\)\(^10\) On the contrary, treatment for HIT carries certain risks.\(^11\) Licensed drugs (argatroban, danaparoid, and lepirudin) are associated with a ~1.0% daily risk of major hemorrhage.\(^12\)\(^-\)\(^14\) Bleeding risk may be greater still in patients misdiagnosed with HIT whose thrombocytopenia is due to a hemorrhagic rather than a prothrombotic diathesis and is compounded by absence of effective reversal agents. Rapid and accurate diagnosis is therefore paramount to avoid the perils of both diagnostic delay and misdiagnosis.

HIT is a clinicopathologic diagnosis, which rests on a compatible clinical picture and laboratory evidence of antiplatelet factor 4 (PF4)/heparin antibodies that activate platelets in a heparin-dependent manner. Rapid and accurate diagnosis is paramount to avoid the perils of misdiagnosis. Clinical evaluation may be guided by scoring systems such as the 4Ts and HIT Expert Probability (HEP) score. Laboratory tests include immunoassays, such as the PF4/heparin enzyme–linked immunosorbent assay (ELISA) and functional tests such as the \(^14\)C-serotonin release assay and heparin-induced platelet activation assay. Clinical scoring systems and commercially available immunoassays have high sensitivity but modest specificity. Functional assays are more specific, but they are technically demanding. Novel laboratory assays with faster turnaround times, greater specificity, and lesser technical complexity are in development. A Bayesian approach that combines the 4T score and the PF4/heparin ELISA result may be used to estimate the probability of HIT and guide clinical decision making.
Clinical and Laboratory Diagnosis of HIT

Table 1 Clinical features that support a diagnosis of heparin-induced thrombocytopenia

<table>
<thead>
<tr>
<th>Features</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fall in platelet count ≥ 50%</td>
<td>Measured from peak platelet count after heparin exposure to nadir platelet count.</td>
</tr>
<tr>
<td>Fall in platelet count begins 5 to 14 days after initial heparin exposure</td>
<td>Fall may occur immediately after heparin re-exposure in patients with a previous recent exposure.</td>
</tr>
<tr>
<td>Nadir platelet count ≥ 20 × 10^9/L</td>
<td>Median nadir platelet count is ~60 × 10^9/L. Nadir may be &lt; 20 × 10^9/L in cases associated with disseminated intravascular coagulation.</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td>May be venous or arterial.</td>
</tr>
<tr>
<td>Unusual clinical manifestations</td>
<td>Skin necrosis at subcutaneous heparin injection sites; anaphylactoid reactions after intravenous heparin bolus; transient global amnesia</td>
</tr>
<tr>
<td>Absence of petechiae and other significant bleeding</td>
<td>Such as infection, drugs other than heparin, recent cardiopulmonary bypass, etc.</td>
</tr>
<tr>
<td>Absence of alternative causes of thrombocytopenia</td>
<td></td>
</tr>
</tbody>
</table>

has poor positive predictive value for HIT owing to the ubiquity of heparin use and thrombocytopenia in hospitalized patients. In a multicenter registry of 2,420 primarily medical patients treated with heparin for 4 or more days, thrombocytopenia occurred in 36.4%, although the incidence of HIT in heparin-treated medical patients is only 0.3 to 0.6%. The incidence of HIT in the critically ill is only 0.8%. Thrombocytopenia is present in 8.3 to 67.6% of patients on admission to an intensive care unit (ICU) and an additional 13.0 to 44.1% acquire thrombocytopenia during their ICU course. At least a quarter of these patients have a history of recent heparin exposure, although the incidence of HIT in the critically ill is only 0.3 to 0.6%. Thus, thrombocytopenia in the vast majority of hospitalized patients with heparin exposure is due to an etiology other than HIT. The great challenge confronting clinicians is to distinguish the relatively uncommon patient with HIT who requires prompt discontinuation of heparin and initiation of a nonheparin anticoagulant from the far more prevalent patient who is thrombocytopenic for other reasons and could be harmed by unnecessary withdrawal of heparin therapy and treatment for HIT.

Careful consideration of additional clinical features is necessary to distinguish HIT from other etiologies of thrombocytopenia. These features are summarized in Table 1 and are reviewed elsewhere. Incorporating these complex features in an estimate of clinical (i.e., pretest) probability can be challenging. To assist clinicians in this process, several clinical scoring systems for HIT have been developed.

4Ts Score

The most extensively studied scoring system, the 4Ts, incorporates four clinical features: (1) magnitude of thrombocytopenia, (2) timing of onset of thrombocytopenia, (3) thrombosis or other clinical sequelae, and (4) the likelihood of other causes of thrombocytopenia. Each feature is assigned a score of 0, 1, or 2 points, yielding a maximum possible summative score of 8. Total scores of 0 to 3, 4 to 5, and 6 to 8 correspond to low, intermediate, and high pretest probabilities, respectively.

Since its initial description, the 4Ts has undergone several modifications. The most widely used version (Table 2) has been evaluated in various clinical settings. In a meta-analysis of 13 studies, the negative predictive value

Table 2 4Ts score

<table>
<thead>
<tr>
<th>Category</th>
<th>2 points</th>
<th>1 point</th>
<th>0 points</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Thrombocytopenia</td>
<td>Platelet count fall &gt; 50% and platelet nadir ≥ 20 × 10^9/L</td>
<td>Platelet count fall 30–50% or platelet nadir 10–19 × 10^9/L</td>
<td>Platelet count fall &lt; 30% or platelet nadir &lt; 10 × 10^9/L</td>
</tr>
<tr>
<td>2. Timing of platelet count fall</td>
<td>Clear onset between days 5 and 10 or platelet fall ≤ 1 day (prior heparin exposure within 30 days)</td>
<td>Consistent with days 5–10 fall, but not clear (e.g., missing platelet counts) or onset after day 10 or fall ≤ 1 day (prior heparin exposure 30–100 days ago)</td>
<td>Platelet count fall &lt; 4 days without recent heparin exposure</td>
</tr>
<tr>
<td>3. Thrombosis or other sequelae</td>
<td>New thrombosis (confirmed) or skin necrosis at heparin injection sites or acute systemic reaction after intravenous heparin bolus</td>
<td>Progressive or recurrent thrombosis or non-necrotizing (erythematous) skin lesions or suspected thrombosis (not proven)</td>
<td>None</td>
</tr>
<tr>
<td>4. Other causes for thrombocytopenia</td>
<td>None apparent</td>
<td>Possible</td>
<td>Definite</td>
</tr>
</tbody>
</table>
of a low probability 4Ts score was 99.8% (95% CI: 97.0–100.0%) and remained high irrespective of the party responsible for scoring, the prevalence of HIT, or the composition of the study population. The positive predictive value of an intermediate (14%, 9–22%) and high probability 4Ts score (64%, 40–82%) was more modest. Limitations in interobserver reliability of the 4Ts system have also been noted with \( \kappa \) coefficients ranging between 0.5 and 0.7.

Table 3 HIT Expert Probability (HEP) Score

<table>
<thead>
<tr>
<th>Clinical features</th>
<th>Points</th>
</tr>
</thead>
</table>
| 1. Magnitude of fall in platelet count  
(measured from peak platelet count to nadir platelet count since heparin exposure) |        |
| <30%              | -1     |
| 30–50%            | 1      |
| >50%              | 3      |
| 2. Timing of fall in platelet count  
For patients in whom typical onset HIT is suspected |        |
| Fall begins <4 days after heparin exposure | -2     |
| Fall begins 4 days after heparin exposure | 2      |
| Fall begins 5–10 days after heparin exposure | 3      |
| Fall begins 11–14 days after heparin exposure | 2      |
| Fall begins >14 days after heparin exposure | -1     |
| For patients with heparin exposure in past 100 days in whom rapid onset HIT is suspected |        |
| Fall begins ≤48 hours after heparin re-exposure | 2      |
| Fall begins >48 hours after heparin re-exposure | -1     |
| 3. Nadir platelet count  
≤ 20 \( \times 10^9 \)/L | -2     |
| > 20 \( \times 10^9 \)/L | 2      |
| 4. Thrombosis (select no more than one)  
For patients in whom typical onset HIT is suspected |        |
| New VTE or ATE occurring ≥4 days after heparin exposure | 3      |
| Progression of preexisting VTE or ATE while receiving heparin | 2      |
| For patients with heparin exposure in past 100 days in whom rapid onset HIT is suspected |        |
| New VTE or ATE after heparin exposure | 3      |
| Progression of preexisting VTE or ATE while receiving heparin | 2      |
| 5. Skin necrosis |        |
| Skin necrosis at subcutaneous heparin injection sites | 3      |
| 6. Acute systemic reaction |        |
| Acute systemic reaction following intravenous heparin bolus | 2      |
| 7. Bleeding |        |
| Presence of bleeding, petechiae, or extensive bruising | -1     |
| 8. Other causes of thrombocytopenia (Select all that apply) |        |
| Presence of a chronic thrombocytopenic disorder | -1     |
| Newly initiated nonheparin medication known to cause thrombocytopenia | -2     |
| Severe infection | -2     |
| Overt DIC (defined as fibrinogen < 100 mg/dL and D-dimer > 5.0 μg/mL) | -2     |
| Indwelling intra-arterial device (e.g., IABP, VAD, and ECMO) | -2     |
| Cardiopulmonary bypass within previous 96 hours | -1     |
| No other apparent cause | 3      |

Abbreviations: ATE, arterial thromboembolism; DIC, disseminated intravascular coagulation; ECMO, extracorporeal membrane oxygenation; IABP, intra-aortic balloon pump; VAD, ventricular-assist device; VTE, venous thromboembolism.
HIT Expert Probability Score

The HIT Expert Probability (HEP) score is based on the opinions of clinical HIT experts from North America. It comprises 8 clinical features including magnitude of platelet count fall, timing of platelet count fall, nadir platelet count, thrombosis, skin necrosis, acute systemic reaction, bleeding, and other causes of thrombocytopenia (►Table 3). Integral weights ranging from −3 (argues strongly against HIT) to +3 (argues strongly in favor of HIT) are assigned to each feature and correspond to the median opinions of the 26 experts on which the model is based. In a retrospective single center study, a cutoff score of 5 was associated with a positive predictive value of 55% (25–82%) and a negative predictive value of 97% (85–100%). Operating characteristics similar to those observed with the 4Ts. The HEP score is more complex and may be more time consuming to apply than the 4Ts. It has not undergone prospective evaluation and definitive cutoffs have not been established. Retrospective comparisons of the HEP score and 4Ts have not demonstrated a significant difference in performance between the two models.

Other Scoring Systems

Several other pretest scoring systems for HIT have been developed but have not been prospectively evaluated. The Lillo-Le Louët score was designed to estimate the probability of HIT in patients following cardiopulmonary bypass (CPB). The model incorporates 3 variables that were predictive of HIT in a derivation set (a biphasic platelet count profile, an interval of ≥5 days from CPB to the first day of suspected HIT, and a CPB duration of ≥118 minutes). In an independent study, it showed a negative predictive value of 78%, suggesting that it may have inadequate sensitivity for use as a clinical screening test.

Laboratory Diagnosis

In light of the challenges of clinical diagnosis, physicians rely heavily on laboratory testing, although this too has (often unrecognized) limitations. Laboratory tests for HIT may be divided into two categories: immunoassays and functional assays. Characteristics of these assays are summarized in ►Table 4 and reviewed in detail later.

### Table 4 General characteristics of diagnostic laboratory assays for HIT

<table>
<thead>
<tr>
<th>Category</th>
<th>Principles</th>
<th>Examples</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
</table>
| Immunoassays    | Detect circulating PF4/heparin antibodies, irrespective of their capacity to activate cells | Polyspecific ELISA  
|                 |                                                                             | IgG-specific ELISA      | High sensitivity, simple to perform, and widely available | Limited specificity               |
| Functional assays | Detect antibodies that activate cells in a heparin-dependent manner | SRA  
|                  |                                                                             | HIPA                     | High sensitivity and high specificity          | Technically difficult and limited availability |

Abbreviations: ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; HIPA, heparin-induced platelet activation assay; IgG, immunoglobulin G; PF4, platelet factor 4; SRA, 14C-serotonin release assay.
results remain common and false-negatives may also occur, particularly at high OD values. It was recently observed that cell-activating and potentially pathogenic antibodies differ from nonpathogenic antibodies with respect to the epitopes to which they bind PF4/heparin complexes. A competitive ELISA that uses KKO, a HIT-like murine monoclonal anti-PF4/heparin IgG, has been developed to exploit this difference. Human cell-activating antibodies inhibit binding of KKO to immobilized PF4/heparin complexes, presumably by competing for the same or overlapping epitopes. Nonactivating human antibodies, in contrast, do not affect KKO binding. In samples from 58 patients with circulating anti-PF4/heparin antibodies, HIT-positive plasma demonstrated greater mean inhibition of KKO binding than HIT-negative plasma (78.9 vs. 26.0%, p < 0.0001). The competitive ELISA showed greater discrimination than the polyspecific or IgG-specific ELISA and may enable discrimination of cell-activating and potentially pathogenic antibodies from nonpathogenic antibodies using an ELISA platform.

An important limitation of the PF4/heparin ELISA is its turnaround time (TAT). Although the analytical TAT is approximately 2 hours, the assay is most cost-effective when multiple patient samples are accommodated in a single run. Many laboratories therefore batch samples and perform the assay no more than once or twice a week, leaving clinicians to make critical initial management decisions without the benefit of laboratory results.

Several rapid immunoassays, designed to accommodate single patient samples and yield results in minutes, have been developed. These include a lateral flow immunoassay using gold nanoparticles, a particle gel immunoassay, a latex particle-enhanced immunoturbidimetric assay, and a polyspecific and IgG-specific chemiluminescence assay. Characteristics of these assays are summarized in Table 5. The principles on which they are based are reviewed elsewhere. All have a TAT of 30 minutes or less and high sensitivity. The particle gel immunoassay appears to have a lower sensitivity (91–94%) than the PF4/heparin ELISA. A negative result may therefore not be sufficient to exclude HIT, particularly if the clinical probability is high. Studies in single reference laboratories suggest that the lateral flow immunoassay and IgG-specific chemiluminescence assay may have greater specificity than the IgG-specific PF4/heparin ELISA. Confirmation in other laboratories is required. The latex particle-enhanced immunoturbidimetric assay and chemiluminescence assays are instrument-based and must be performed on proprietary analyzers. A rapid particle immunofiltration assay is approved in the United States, but published data suggest that it has unacceptable diagnostic accuracy and experts do not recommend its use.

### Functional Assays

Functional assays are more specific than commercially available immunoassays because they detect only the subset of antibodies that have the capacity to induce platelet activation in a heparin-dependent manner. The prototypical functional assays are the 14C-serotonin release assay (SRA) and the heparin-induced platelet activation assay (HIPA). In the SRA, various concentrations of heparin and heat-inactivated patient serum are added to washed donor platelets radio-labeled with 14C. A positive test is signified by heparin-dependent release of 14C-serotonin. The HIPA is based on a similar principle but uses visual assessment of platelet aggregation as an endpoint. The sensitivity and specificity of the SRA and HIPA are said to exceed 95%, although universally accepted reference standards against which to measure their performance do not exist. Other washed platelet assays that use ATP release detected by lumaggregometry, platelet-derived microparticle generation detected by flow cytometry, and proteolysis of FcγRIIa (the receptor through which HIT immune complexes activate platelets) detected by chemiluminescence have been described but require independent validation.

Assays that use citrated platelet-rich plasma (PRP) rather than washed platelets include the platelet aggregation test (PAT); a modification of the 14C-SRA, and flow cytometry-based assays that use annexin V-binding, serotonin release, P-selectin expression, or platelet microparticle formation as a readout. Studies comparing the PAT with a washed platelet assay suggest that the former has lower

<table>
<thead>
<tr>
<th>Assay</th>
<th>Antibody class detection</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Turnaround time (minutes)</th>
<th>Regulatory approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lateral flow immunoassay</td>
<td>IgG</td>
<td>1.00</td>
<td>0.93</td>
<td>15</td>
<td>Europe</td>
</tr>
<tr>
<td>Particle gel immunoassay</td>
<td>IgG</td>
<td>0.91–0.94</td>
<td>0.87–0.95</td>
<td>20</td>
<td>Asia, Canada, Europe</td>
</tr>
<tr>
<td>Latex particle-enhanced immunoturbidimetric assay</td>
<td>IgG, IgA, IgM</td>
<td>1.00</td>
<td>0.76</td>
<td>13</td>
<td>Europe</td>
</tr>
<tr>
<td>Chemiluminescence assay</td>
<td>IgG, IgA, IgM</td>
<td>0.98–1.00</td>
<td>0.73–0.82</td>
<td>30</td>
<td>Europe</td>
</tr>
<tr>
<td>Chemiluminescence assay</td>
<td>IgG</td>
<td>0.96–1.00</td>
<td>0.85–0.97</td>
<td>30</td>
<td>Europe</td>
</tr>
</tbody>
</table>

Abbreviation: HIT, heparin-induced thrombocytopenia.
sensitivity (33% to 81%) and may miss cases of true HIT. For this reason, an international consensus panel recommends against use of the PAT. Comparisons between washed platelet assays and other PRP-based tests are lacking. A whole blood assay that uses impedance platelet aggregometry has also been described. This system demonstrated a sensitivity and specificity of 90.3 and 89.0%, respectively, in a multicenter Australian study.

The major disadvantage of washed platelet assays is that they are technically demanding. Both the SRA and HIPA require fresh reactive donor platelets, the SRA requires radioisotope, and the HIPA relies on meticulous technique, and the use of a subjective visual endpoint. These reagents and methods are impracticable for most clinical laboratories and restrict the use of functional assays to a small number of reference laboratories. Even among such laboratories, test methodologies, result interpretation, and reporting are not well-standardized.

A novel functional assay that may overcome technical limitations inherent to washed platelet assays was recently described. The assay utilizes a chicken B-lymphocyte line transfected with the human FcγRIIa receptor coupled to a luciferase reporter. When appropriate concentrations of PF4, heparin, and dilute HIT plasma are added to the system, HIT immune complexes bind to the receptor and induce an intracellular signaling cascade, ultimately leading to luciferase activation and emission of light. In a study of this assay in 58 patients with suspected HIT and circulating PF4/heparin antibodies, SRA-positive plasma induced significantly greater mean luciferase activity than SRA-negative plasma (3.14-fold basal vs. 0.96-fold basal, \( p < 0.0001 \)). Using a positive SRA and an intermediate or high probability 4Ts score as the reference standard, the assay correctly classified more patients (51/58) than a commercially available polyspecific (45/58) or IgG-specific (42/58) ELISA. It may be feasibly employable in a greater number of clinical laboratories than the SRA or HIPA because it replaces platelets with a cell-line that can be stored in a freezer and retrieved for use as needed and uses light emission, rather than radioactivity or platelet aggregation, as an endpoint for cellular activation. Prospective evaluation of this assay in a larger cohort of patients is awaited.

**An Evidence-Based Bayesian Approach to Diagnosis**

The diagnostic tools most widely available to clinicians are clinical assessment and the PF4/heparin ELISA. An

![Fig. 1](image)

**Fig. 1** Evidence-based Bayesian approach to the diagnosis of HIT. The figure depicts one approach to the evaluation of patients with suspected HIT. Clinical probability estimates for a low (0–3), intermediate (4–5), and high (6–8) probability 4T score, derived from a meta-analysis, are shown. Patients with a low probability 4T score have a very low likelihood of HIT and do not require HIT laboratory testing. Testing with a sensitive immunoassay should be considered in patients with an intermediate or high probability score. If an ELISA is performed, the OD may be used to refine the estimated probability of HIT. Likelihood ratios for various OD strata are shown. These likelihood ratios were derived using a commercially available polyspecific ELISA (GTI PF4 Enhanced, Gen-Probe GTI Diagnostics, Waukesha, WI) in a single institution and may not apply to other assays or other laboratories. The clinical probability (after conversion to clinical odds) may be multiplied by the likelihood ratio to estimate the posttest odds of HIT (which, in turn, may be converted to posttest probability). For simplicity, only probabilities (and not odds) are shown. Clinical suggestions for further evaluation and management based on the estimated probability of HIT are provided. This approach may be used as a guide, but it should not supersede clinical judgment.
evidence-based Bayesian approach that integrates the 4T score and the OD value determined by PF4/heparin ELISA testing may be used to estimate the posttest probability of HIT and guide clinical decision-making.

One such approach is depicted in –Fig. 1. In this approach, the 4Ts score is used to estimate the clinical (pretest) probability of HIT. Patients with a low probability 4Ts score have a very low likelihood of HIT and do not require HIT laboratory testing. Testing with a sensitive immunoassay should be considered in patients with an intermediate or high probability score. If an ELISA is performed, the OD may be used to refine the estimated probability of HIT. The clinical probability and likelihood ratio associated with a given OD value may be used to estimate the posttest probability of HIT. The estimated probability of HIT, in turn, may inform decisions about further clinical evaluation and management.

Conclusion

Rapid and accurate diagnosis of HIT is both challenging and of critical clinical importance. Clinical scoring systems such as the 4Ts and HEP score have high negative predictive value and permit an estimation of the clinical probability of HIT but have limited specificity and have not been directly compared with standard intuition-based clinical diagnosis. Similar to clinical scoring systems, immunoassays are highly sensitive, but they lack adequate specificity at manufacturer-recommended cutoffs to rule in HIT. Washed platelet functional assays are both sensitive and specific, but they are restricted to select reference laboratories due to meticulous technical requirements. The need for fresh and responsive donor platelets also restricts the use of these assays and remains a potential source of poor performance in inexperienced hands.

Evidence-based Bayesian approaches to diagnosis that integrate clinical assessment and immunoassay testing, the two most widely used diagnostic tools in current practice, facilitate estimation of the posttest probability of HIT, and may guide clinical decision making (–Fig. 1). Also in development are novel laboratory tests that are less technically demanding, more specific, do not rely on fresh responsive donor platelets and have shorter TATs than existing assays. These advancements are likely to presage more exacting diagnosis and management and better outcomes for patients with suspected HIT.

Acknowledgment

This work was supported by HL112903 to AC.

References

Lo GK, Sigouin CS, Warkentin TE. What is the potential for
Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJH.
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A.
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A.
Cuker A. Heparin-induced thrombocytopenia: present and future.
Warkentin TE, Heddle NM. Laboratory diagnosis of immune
2(2):148–157
Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A.
Evaluation of pretest clinical score (4 T’s) for the diagnosis of
heparin-induced thrombocytopenia in two clinical settings. J
Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value
of the 4Ts scoring system for heparin-induced thrombocytopenia:
a systematic review and meta-analysis. Blood 2012;120(20):
4160–4167
(HEP) Score: a novel pre-test probability model for heparin-
duced thrombocytopenia based on broad expert opinion. J
Thromb Haemost 2010;8(12):2642–2650
Strutt JK, Mackey JE, Johnson SM, Sylvia LM. Assessment of the 4Ts
pretest clinical scoring system as a predictor of heparin-induced
Nagler M, Fabbro T, Wuijlenmin WA. Prospective evaluation of the
interobserver reliability of the 4Ts score in patients with suspected
10(1):151–152
Uaprasert N, Cheaksangwhuana C, Akkawat B, Rojnuckarin P.
Comparison of diagnostic performance of the heparin-induced
thrombocytopenia expert probability and the 4Ts score in screen-
ing for heparin-induced thrombocytopenia. Blood Coagul Fibrino-
lysis 2013;24(3):261–268
Farahani N, Kitahara S, Tcherniantchouk O. Prospective compari-
sion of the HIT expert probability (HEP) score versus the Warkentin
4T’s score in a quaternary care center. [abstract] Thromb Haemost
2013;111(s2):936
score for heparin-induced thrombocytopenia after cardiopulmo-
Mesmmore HL, Fabbriini N, Bird ML, et al. Simple scoring system for
early management of heparin-induced thrombocytopenia. Clin
Appl Thromb Hemost 2011;17(2):197–201
thrombocytopenia after cardiac surgery: an observational study
585–590
Bakchoul T, Giptner A, Najouei A, Bein G, Santoso S, Sachs UJH.
Prospective evaluation of PF4/heparin immunoassays for the
diagnosis of heparin-induced thrombocytopenia. J Thromb Hae-
most 2009;7(8):1260–1265
Lo GK, Sigouin CS, Warkentin TE. What is the potential for
overdiagnosis of heparin-induced thrombocytopenia? Am J Hem-
atol 2007;82(12):1037–1043
Greinacher A, Juhl D, Strobel U, et al. Heparin-induced thrombo-
cytopenia: a prospective study on the incidence, platelet-activat-
ing capacity and clinical significance of antiplatelet factor 4/
heparin antibodies of the IgG, IgM, and IgA classes. J Thromb
Haemost 2007;5(8):1666–1673
Incidence and clinical significance of anti-PF4/heparin antibodies
of the IgG, IgM, and IgA class in 755 consecutive patient samples
referred for diagnostic testing for heparin-induced thrombocyto-
Zwicker JJ, Ulh I, Huang WY, Shaz BH, Bauer KA. Thrombosis and
ELISA optical density values in hospitalized patients with heparin-
2133–2137
Warkentin TE, Sheppard JJ, Moore JC, Sigouin CS, Kelton JG.
Quantitative interpretation of optical density measurements using
PF4-dependent enzyme-immunoassays. J Thromb Haemost 2008;
6(8):1304–1312
Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical
interpretation of the anti-platelet factor 4/heparin enzyme-linked
immunosorbent assay for the diagnosis of heparin-induced
thrombocytopenia through the use of receiver operating charac-
teristic analysis, stratum-specific likelihood ratios, and bayes
Cuker A, Ortel TL. ASH evidence-based guidelines: is the IgG-
specific anti-PF4/heparin ELISA superior to the polyspecific ELISA
in the laboratory diagnosis of HIT? Hematology (Am Soc Hematol
Educ Program) 2009;***:250–252
Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL.
Validation of the high-dose heparin confirmatory step for the
diagnosis of heparin-induced thrombocytopenia. Blood 2010;
116(10):1761–1766
Warkentin TE, Sheppard JJ. No significant improvement in diag-
nostic specificity of an anti-PF4/polyanion immunoassay with use
of high heparin confirmatory procedure. J Thromb Haemost 2006;
4(1):281–282
Selleng S, Schreier N, Wollert HG, Greinacher A. The diagnostic
value of the anti-PF4/heparin immunoassay high-dose heparin
confirmatory test in cardiac surgery patients. Anesth Analg 2011;
112(4):774–776
Sachs BS, Litvinov RI, Varovoi SV, et al. Dynamic antibody-
binding properties in the pathogenesis of HIT. Blood 2012;
120(5):1137–1142
Cuker A, Rux AH, Hinds JL, et al. Novel diagnostic assays for heparin-
Sachs UJ, von Hesberg J, Santoso S, Bein G, Bakchoul T. Evaluation of
a new nanoparticle-based lateral-flow immunoassay for the ex-
clusion of heparin-induced thrombocytopenia (HIT). Thromb Hae-
most 2011;106(6):1197–1202
Meyer O, Salama A, Pittet N, Schwind P. Rapid detection of heparin-
induced platelet antibodies with particle gel immunoassay (ID-
Bakchoul T, Giptner A, Najouei A, Bein G, Santoso S, Sachs UJH.
Prospective evaluation of PF4/heparin immunoassays for the
diagnosis of heparin-induced thrombocytopenia. J Thromb Hae-
most 2009;7(8):1260–1265
Davidson SJ, Ortel TL, Smith LJ. Performance of a new, rapid,
automated immunoassay for the detection of anti-platelet factor
4/heparin complex antibodies. Blood Coagul Fibrinolysis 2011;
22(4):340–344
immunoassays in the diagnosis of heparin induced thrombocyto-
Legnani C, Cini M, Pili C, Boggian O, Frascarico M, Palareti G.
Evaluation of a new automated panel of assays for the detection
of anti-PF4/heparin antibodies in patients suspected of having
heparin-induced thrombocytopenia. Thromb Haemost 2010;
104(2):402–409

Seminars in Thrombosis & Hemostasis Vol. 40 No. 1/2014
This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.

Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-Induced Thrombocytopenia. Boca Raton Informa; 2013: 272–314


